Skip to main content

Advertisement

SpringerLink
Log in

Bleeding Risk Prediction Models in Atrial Fibrillation

  • Invasive Electrophysiology and Pacing (EK Heist, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Novel, nonvitamin K antagonist oral anticoagulants (OACs) have demonstrated similar or superior efficacy to warfarin for ischemic stroke prevention in patients with atrial fibrillation (AF). As the prevalence of AF rises in a growing elderly population, these agents are becoming central to the routine practice of clinicians caring for these patients. Though the benefits are clear, the decision to treat the elderly patient with AF with long-term oral OACs is often a dilemma for the clinician mindful of the risk of major bleeding. Several bleeding risk prediction models have been created to help the clinician identify patients for whom the risk of bleeding is high, and would potentially outweigh the benefits of OAC therapy. In this review, we discuss the features of 8 bleeding risk prediction models, including the recently described HEMORR2HAGES, HAS-BLED, and ATRIA models, and approaches to assessing bleeding risk in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance •• Of major importance

  1. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:546S–92.

    Article  CAS  PubMed  Google Scholar 

  2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  4. • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. Apixaban was superior to warfarin in preventing stroke and caused less bleeding.

    Article  CAS  PubMed  Google Scholar 

  5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–9.

    Article  PubMed  Google Scholar 

  6. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.

    Article  PubMed  Google Scholar 

  7. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272–4.

    Article  CAS  PubMed  Google Scholar 

  8. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997–1011.

    Article  CAS  PubMed  Google Scholar 

  9. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650–6.

    Article  PubMed  Google Scholar 

  10. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–52.

    Article  CAS  PubMed  Google Scholar 

  11. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–9.

    Article  CAS  PubMed  Google Scholar 

  12. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725–33.

    Article  CAS  PubMed  Google Scholar 

  13. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 1998;13:311–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Aspinall SL, DeSanzo BE, Trilli LE, Good CB. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005;20:1008–13.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457–60.

    Article  CAS  PubMed  Google Scholar 

  16. Investigators TC. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657–62.

    Article  Google Scholar 

  17. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.

    Article  CAS  PubMed  Google Scholar 

  18. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.

    Article  PubMed  Google Scholar 

  19. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.

    Article  PubMed  Google Scholar 

  20. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.

    Article  CAS  PubMed  Google Scholar 

  21. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612–7.

    Article  PubMed  Google Scholar 

  22. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.

    CAS  PubMed  Google Scholar 

  24. •• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100. This study presents a novel bleeding risk score as a practicle tool to assess the bleeding risk of patients with atrial fibrillation.

    Article  PubMed  Google Scholar 

  25. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;29:1181–9.

    Article  PubMed  Google Scholar 

  26. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–34.

    Article  PubMed  Google Scholar 

  27. •• Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. J Am Coll Cardiol. 2011;57:173–80. This study investigated predictors of bleeding in a cohort of anticoagulated patients and determined that the HAS-BLED score performed the best in predicting rates of major bleeding compared with other algorithms.

    Article  CAS  PubMed  Google Scholar 

  28. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–36.

    Article  PubMed  Google Scholar 

  29. •• Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared with warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861–7. Three bleeding risk scores were compared and the HAS-BLED score performed better than HEMORR(2)HAGES and ATRIA in predicting clinically relavant bleeding including intracranial hemorrhage.

    Article  PubMed  Google Scholar 

  30. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, noninferiority trial. Lancet. 2008;371:315–21.

    Article  CAS  PubMed  Google Scholar 

  31. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012;5:941–8.

    Article  PubMed  Google Scholar 

  32. Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. Int J Epidemiol. 2011;40:1094–105.

    Article  PubMed  Google Scholar 

  33. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011;173:1327–35.

    Article  PubMed  Google Scholar 

  34. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362–7.

    Article  CAS  PubMed  Google Scholar 

  35. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163:1580–6.

    Article  PubMed  Google Scholar 

  36. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its nonuse at a veterans affairs medical center. Am J Cardiol. 2000;85:568–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Isac C. Thomas declares that he has no conflict of interest. Matthew Sorrentino declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Cardiology, University of Chicago, 5841 S. Maryland Ave, MC 6080, Chicago, IL, 60637, USA

    Isac C. Thomas & Matthew J. Sorrentino

Authors
  1. Isac C. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J. Sorrentino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Sorrentino.

Additional information

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, I.C., Sorrentino, M.J. Bleeding Risk Prediction Models in Atrial Fibrillation. Curr Cardiol Rep 16, 432 (2014). https://doi.org/10.1007/s11886-013-0432-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-013-0432-9

Keywords

Search

Navigation